Physiological role and clinical utility of inositols in polycystic ovary syndrome

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 37, Issue , 2016, Pages 129-139

  Bevilacqua, Arturo ^a,b   Bizzarri, Mariano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Research Center of Neurobiology Daniel Bovet   (Italy)

Author keywords

D chiroinositol; inositol; insulin; myoinositol; polycystic ovary syndrome

Indexed keywords

D CHIROINOSITOL; INOSITOL; UNCLASSIFIED DRUG;

BIOCHEMISTRY; CELL FUNCTION; EMBRYO DEVELOPMENT; FEMALE; FERTILITY; GYNECOLOGIC DISEASE; HUMAN; OOCYTE DEVELOPMENT; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REPRODUCTION; REVIEW; HYPERINSULINISM; INSULIN RESISTANCE; METABOLISM; POLYCYSTIC OVARY SYNDROME; STEREOISOMERISM;

FEMALE; HUMANS; HYPERINSULINISM; INOSITOL; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; STEREOISOMERISM;

EID: 84963987439     PISSN: 15216934     EISSN: 15321932     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2016.03.007     Document Type: Review

References (104)

1. [1] Thomas, M.P., Mills, S.J., Potter, B.V., The “Other” inositols and their phosphates: synthesis, biology, and medicine (with recent advances in myo-inositol chemistry). Angew Chem Int Ed Engl 54 (2015), 2–39.
2. [2] Bizzarri, M., Carlomagno, G., Inositol: history of an effective therapy for polycystic ovary syndrome. Eur Rev Med Pharmacol Sci 18:13 (2014), 1896–1903.
3. [3] Hoglan, F.A., Bartow, E., Inactive inositol and its derivatives. Ind Eng Chem 31:6 (1939), 749–750.
4. *[4] Holub, B.J., Metabolism and function of myo-inositol and inositol phospholipids. Annu Rev Nutr 6 (1986), 563–597.
5. [5] Majumder, A.L., Biswas, B.B., (eds.) Biology of inositols and phosphoinositides, 2010, Springer, Berlin.
6. [6] Falasca, M., (eds.) Phosphoinositides and disease, 2012, Springer, Berlin.
7. [7] Palatnik, A., Frolov, K., Fux, M., et al. Doubleblind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharm 21 (2001), 335–339.
8. [8] Pasta, V., Gullo, G., Giuliani, A., et al. An association of boswellia, betaine and myo-inositol (eumastós®) in the treatment of mammographic breast density: a randomized, double-bind study. Eur Rev Med Pharmacol Sci 19:22 (2015), 4419–4426.
9. [9] Vucenik, I., Shamsuddin, A.M., Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic. J Nutr 133:11 Suppl 1 (2003 Nov), 3778S–3784S.
10. [10] Huang, L.C., Fonteles, M.C., Houston, D.B., et al. Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypo- glycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocin-diabetic rats in vivo. Endocrinology 132 (1993), 652–657.
11. [11] Sun, T.H., Heimark, D.B., Nguygen, T., et al. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun 293 (2002), 1092–1098.
12. [12] Berridge, M.J., Inositol trisphosphate and calcium oscillations. Adv Second Messenger Phosphoprotein Res 26 (1992), 211–223.
13. [13] Downes, C.P., Macphee, C.H., Myo-inositol metabolites as cellular signals. Eur J Biochem 193:1 (1990), 1–18.
14. [14] Strange, K., Morrison, R., Heilig, C.W., et al. Upregulation of inositol transport mediates inositol accumulation in hyperosmolar brain cells. Am J Physiol 260:4 Pt 1 (1991), C784–C790.
15. [15] Di Paolo, G., De Camilli, P., Phosphoinositides in cell regulation and membrane dynamics. Nature 443 (2006), 651–657.
16. [16] Thomas, R.M., Nechamen, C.A., Mazurkiewicz, J.E., et al. The adapter protein APPL1 links FSH receptor to inositol 1,4,5-trisphosphate production and is implicated in intracellular Ca(2+) mobilization. Endocrinology 152 (2011), 1691–1701.
17. [17] Heimark, D., McAllister, J., Larner, J., Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J 61 (2014), 111–117.
18. [18] Downes, C.P., The cellular functions of myo-inositol. Biochem Soc Trans 17 (1989), 259–268.
19. [19] Downes, C.P., Macphee, C.H., Myo-inositol metabolites as cellular signals. Eur J Biochem 193 (1990), 1–18.
20. *[20] Beemster, P., Groenen, P., Steegers-Theunissen, R., Involvement of inositol in reproduction. Nutr Rev 60 (2002), 80–87.
21. [21] Quirk, J.G. Jr., Bleasdale, J.E., Myo-inositol homeostasis in the human fetus. Obstet Gynecol 62 (1983), 41–44.
22. [22] Greene, N.D.E., Copp, A.J., Inositol prevents folate resistant neural tube defects in the mouse. Nat Med 3 (1997), 60–66.
23. [23] Cavalli, P., Copp, A.J., Inositol and folate resistant neural tube defects. J Med Genet, 39, 2002, E5.
24. [24] Larner, J., D-chiro-inositol–its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 3:1 (2002), 47–60.
25. [25] Scioscia, M., Nigro, M., Montagnani, M., The putative metabolic role of d-chiro inositol phosphoglycan in human pregnancy and preeclampsia. J Reprod Immunol 101–102 (2014), 140–147.
26. [26] Lin, X., Ma, L., Gopalan, C., et al. d-chiro-Inositol is absorbed but not synthesized in rodents. Br J Nutr 102:10 (2009), 1426–1434.
27. [27] Cogram, P., Tesh, S., Tesh, J., et al. D-chiro-inositol is more effective than myo-inositol in preventing folate-resistant mouse neural tube defects. Hum Reprod 17:9 (2002), 2451–2458.
28. [28] Nascimento, N.R., Lessa, L.M., Kerntopf, M.R., et al. Inositols prevent and reverse endothelial dysfunction in diabetic rat and rabbit vasculature metabolically and by scavenging superoxide. Proc Natl Acad Sci USA 103:1 (2006), 218–223.
29. [29] Yu, J., Choi, S., Park, E.S., et al. D-chiro-inositol negatively regulates the formation of multinucleated osteoclasts by down-regulating NFATc1. J Clin Immunol 32:6 (2012), 1360–1371.
30. [30] D'Anna, R., Di Benedetto, V., Rizzo, P., et al. Myo-inositol may prevent gestational diabetes in PCOS women. Gynecol Endocrinol 28:6 (2012), 440–442.
31. [31] D'Anna, R., Scilipoti, A., Giordano, D., et al. Myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care 36:4 (2013), 854–857.
32. *[32] Chiu, T.T., Tam, P.P., A correlation of the outcome of clinical in vitro fertilization with the inositol content and embryotrophic properties of human serum. J Assist Reprod Genet 9:6 (1992), 524–530.
33. [33] Chiu, T.T., Rogers, M.S., Law, E.L., et al. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod 17 (2002), 1591–1596.
34. [34] Ciotta, L., Stracquadanio, M., Pagano, I., et al. Effects of Myo-Inositol supplementation on oocyte's quality in PCOS patients: a double blind trial. Eur Rev Med Pharmacol Sci 15:4 (2011), 509–514.
35. [35] Papaleo, E., Unfer, V., Baillargeon, J.P., et al. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 91:5 (2009), 1750–1754.
36. [36] Unfer, V., Carlomagno, G., Rizzo, P., et al. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci 15:4 (2011), 452–457.
37. *[37] Colazingari, S., Treglia, M., Najjar, R., et al. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet 288:6 (2013), 1405–1411.
38. [38] Lisi, F., Carfagna, P., Oliva, M.M., et al. Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reprod Biol Endocrinol, 23(10), 2012, 52.
39. [39] Pal, L., Jindal, S., Witt, B.R., et al. Less is more… Increased gonadotropin use for ovarian stimulation adversely influences clinical pregnancy and live birth following IVF. Fertil Steril 89:6 (2008), 1694–1701.
40. [40] Zacchè, M.M., Caputo, L., Filippis, S., et al. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 25 (2009), 508–513.
41. [41] Matsuda, M., Tsutsumi, K., Kanematsu, T., et al. Involvement of phospholipase C-related inactive protein in the mouse reproductive system through the regulation of gonadotropin levels. Biol Reprod 81 (2009), 681–689.
42. [42] Goud, P.T., Goud, A.P., Van Oostveldt, P., et al. Presence and dynamic redistribution of type I inositol 1,4,5-trisphosphate receptors in human oocytes and embryos during in-vitro maturation, fertilization and early cleavage divisions. Mol Hum Reprod 5 (1999), 441–451.
43. [43] Lowther, K.M., Weitzman, V.N., Maier, D., et al. Maturation, fertilization, and the structure and function of the endoplasmic reticulum in cryopreserved mouse oocytes. Biol Reprod 81 (2009), 147–154.
44. [44] Chiu, T.T., Rogers, M.S., Briton-Jones, C., et al. Effects of myo- inositol on the in-vitro maturation and subsequent development of mouse oocytes. Hum Reprod 18 (2003), 408–416.
45. [45] Holm, P., Booth, P.J., Schmidt, M.H., et al. High bovine blastocyst development in a static in vitro production system using SOFaa medium supplemented with sodium citrate and myo-inositol with or without serum-proteins. Theriogenology 52:4 (1999), 683–700.
46. [46] Warner, S.M., Conlon, F.V., Kane, M.T., Inositol transport in preimplantation rabbit embryos: effects of embryo stage, sodium, osmolality and metabolic inhibitors. Reproduction 125:4 (2003), 479–493 Erratum in: Reproduction 2005; 129(1): 128.
47. [47] Kwon, H.M., Yamauchi, A., Uchida, S., et al. Cloning of the cDNA for a Na+/myo-inositol cotransporter, a hypertonicity stress protein. J Biol Chem 267 (1992), 6297–6301.
48. [48] Higgins, B.D., Kane, M.T., Inositol transport in mouse oocytes and preimplantation embryos: effects of mouse strain, embryo stage, sodium and the hexose transport inhibitor, phloridzin. Reproduction 125 (2003), 111–118.
49. [49] Kane, M.T., Norris, M., Harrison, R.A.P., Uptake and incorporation of inositol by preimplantation mouse embryos. J Reprod Fertil 96 (1992), 617–625.
50. [50] Ajduk, A., Ciemerych, M.A., Nixon, V., et al. Fertilization differently affects the levels of cyclin B1 and M-phase promoting factor activity in maturing and metaphase II mouse oocytes. Reproduction 136 (2008), 741–752.
51. [51] Stachecki, J.J., Armant, D.R., Transient release of calcium from inositol 1,4,5-trisphosphate-specific stores regulates mouse preimplantation development. Development 122 (1996), 2485–2496.
52. *[52] Colazingari, S., Fiorenza, M.T., Carlomagno, G., et al. Improvement of mouse embryo quality by myo-inositol supplementation of IVF media. J Assist Reprod Genet 31 (2014), 463–469.
53. [53] March, W.A., Moore, V.M., Willson, K.J., et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 25 (2010), 544–551.
54. [54] The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19 (2004), 41–47.
55. [55] Dunaif, A., Segal, K.R., Futterweit, W., et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:9 (1989), 1165–1174.
56. [56] Dunaif, A., Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18 (1997), 774–800.
57. [57] Toprak, S., Yonem, A., Cakir, B., et al. Insulin resistance in nonobese patients with polycystic ovary syndrome. Horm Res 55 (2001), 65–70.
58. [58] Palomba, S., Falbo, A., Zullo, F., et al. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 30 (2009), 1–50.
59. [59] Kolodziejczyk, B., Duleba, A.J., Spaczynski, R.Z., et al. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 73 (2000), 1149–1154.
60. [60] Trolle, B., Flyvbjerg, A., Kesmodel, U., et al. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled crossover trial. Hum Reprod 22 (2007), 2967–2973.
61. [61] Palomba, S., Falbo, A., Di Cello, A., et al. Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlledtrial. Fertil Steril 96 (2011), 1128–1133.
62. [62] ACOG Committee on Practice Bulletins Gynaecology, ACOG Practice BulletinNo. 108: polycystic ovary syndrome. Obstet Gynecol 114 (2009), 936–949.
63. [63] Bourg, C.A., Phillips, B.B., Rosiglitazone, myocardial ischemic risk, and recent regulatory actions. Ann Pharmacother 46 (2012), 282–289.
64. [64] Baillargeon, J.P., Iuorno, M.J., Jakubowicz, D.J., et al. Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004), 242–249.
65. [65] Goel, M., Azev, V.N., d'Alarcao, M., The biological activity of structurally defined inositol glycans. Future Med Chem 1:1 (2009), 95–118.
66. [66] Ortmeyer, H.K., Dietary myoinositol results in lower urine glucoseand in lower postprandial plasma glucose in obese insulin resistantrhesus monkeys. Obes Res 4 (1996), 569–575.
67. [67] Baillargeon, J.P., Nestler, J.E., Ostlund, R.E., et al. Greek hyperinsulinemic women,with or without polycystic ovary syndrome, display altered inositols metabolism. Hum Reprod 23 (2008), 1439–1446.
68. [68] Baillargeon, J.P., Iuorno, M.J., Apridonidze, T., et al. Uncoupling between insulin and release of a D-Chiro-Inositol-Containing Inositol phosphoglycan mediator of insulin action in obese women with Polycystic Ovary Syndrome. Metab Syndr Relat Disord 8 (2010), 127–136.
69. [69] Iuorno, M.J., Jakubowicz, D.J., Baillargeon, J.P., et al. Effects of D-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 8 (2002), 417–423.
70. [70] Nestler, J.E., Jakubowicz, D.J., Reamer, P., et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 340 (1999), 1314–1320.
71. [71] Gerli, S., Mignosa, M., Di Renzo, G.C., Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci 7 (2003), 151–159.
72. [72] Cheang, K.I., Baillargeon, J.P., Essah, P.A., et al. Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism 57 (2008), 1390–1397.
73. [73] Isabella, R., Raffone, E., Does ovary need D-chiro-inositol?. J Ovarian Res, 5, 2012, 14.
74. [74] Palomba, S., Falbo, A., Di Cello, A., et al. Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial. Fertil Steril 96 (2011), 1128–1133.
75. [75] Nestler, J.E., Jakubowicz, D.J., de Vargas, A.F., et al. Insulin stimulates testosterone biosynthesis by humanthecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 83 (1998), 2001–2005.
76. [76] Rubin, L.J., Hale, C.C., Characterization of a Mg-dependent, Na-inositol co-transport process in cardiac sarcolemmal vesicles. J Mol Cell Cardiol 25:6 (1993), 721–731.
77. [77] Unfer, V., Carlomagno, G., Papaleo, E., et al. Hyperinsulinemia alters myoinositol to D-chiroinositol ratio in the follicular fluid of patients with PCOS. Reprod Sci 21 (2014), 854–858.
78. [78] Asplin, I., Galasko, G., Larner, J., chiro-Inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci USA 90 90:13 (1993), 5924–5928.
79. [79] Rice, S., Christoforidis, N., Gadd, C., et al. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum Reprod 20 (2005), 373–381.
80. [80] Heimark, D., McAllister, J., Larner, J., Decreased myo-inositol to chiro-inositol (m/c) ratios and increased m/c epimerase activity in pcos theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J 61 (2013), 111–117.
81. [81] Carlomagno, G., Unfer, V., Roseff, S., The D-chiro-inositol paradox in the ovary. Fertil Steril 95 (2011), 2515–2516.
82. [82] Vitagliano, A., Quaranta, M., Noventa, M., et al. ‘‘Empiric’’ inositol supplementation in normal-weight non insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects. Arch Gynecol Obstet 291:5 (2015), 955–957.
83. [83] Croze, M.L., Vella, R.E., Pillon, N.J., et al. Chronic treatment with myo-inositol reduces white adipose tissue accretion and improves insulin sensitivity in female mice. J Nutr Biochem 24:2 (2013), 457–466.
84. [84] Dang, N.T., Mukai, R., Yoshida, K., et al. D-pinitol and myo-inositol stimulate translocation of glucose transporter 4 in skeletal muscle of C57BL/6 mice. Biosci Biotechnol Biochem 74:5 (2010), 1062–1067.
85. [85] Gerli, S., Papaleo, E., Ferrari, A., et al. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 11 (2007), 347–354.
86. [86] Kamenov, Z., Kolarov, G., Gateva, A., et al. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol Endocrinol 31:2 (2015), 131–135.
87. [87] Costantino, D., Minozzi, G., Minozzi, E., et al. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci 13 (2009), 105–110.
88. [88] Genazzani, A.D., Lanzoni, C., Ricchieri, F., et al. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 24 (2008), 139–144.
89. [89] Morgante, G., Orvieto, R., Di Sabatino, A., et al. The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen. Fertil Steril 95 (2011), 2642–2644.
90. [90] Minozzi, M., D'Andrea, G., Unfer, V., Treatment of hirsutism with myo-inositol: a prospective clinical study. Reprod Biomed Online 17 (2008), 579–582.
91. [91] Facchinetti, F., Dante, G., Neri, I., The ratio of MI to DCI and its impact in the treatment of polycystic ovary syndrome: experimental and literature evidences. Front Gynaecol Endocrinol ISGE Series (2015), 103–109.
92. *[92] Dinicola, S., Chiu, T.T., Unfer, V., et al. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome. J Clin Pharmacol 54 (2014), 1079–1092.
93. [93] Lowther, K.M., Weitzman, V.N., Maier, D., et al. Maturation, fertilization, and the structure and function of the endoplasmic reticulum in cryopreserved mouse oocytes. Biol Reprod 81 (2009), 147–154.
94. [94] Janovick, J.A., Conn, P.M., Gonadotropin-releasing hormone (GnRH)-receptor coupling to inositol phosphate and prolactin production in GH3 cells stably transfected with rat GnRH receptor complementary deoxyribonucleic acid. Endocrinology 135 (1994), 2214–2219.
95. [95] Nestler, J.E., Insulin and insulin-like growth factor-I stimulate the 3 beta-hydroxysteroid dehydrogenase activity of human placental cytotrophoblasts. Endocrinology 125 (1989), 2127–2133.
96. [96] Nestler, J.E., Modulation of aromatase and P450 cholesterol side-chain cleavage enzyme activities of human placental cytotrophoblasts by insulin and insulin-like growth factor I. Endocrinology 121 (1987), 1845–1852.
97. [97] Noventa, M., Quaranta, M., Vitagliano, A., et al. May underdiagnosed nutrition imbalances be responsible for a portion of so-called unexplained infertility? From diagnosis to potential treatment options. Reprod Sci, 2015 Dec 20 pii: 1933719115620496.
98. [98] Bizzarri, M., Cucina, A., Harrath, A.H., et al. Does Myo-Inositol effect on PCOS follicles involve cytoskeleton regulation?. Med Hypotheses 91 (2016), 1–5.
99. *[99] Jonard, S., Dewailly, D., The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 10 (2004), 107–117.
100. *[100] Nestler, J.E., Unfer, V., Reflections on inositol(s) for PCOS therapy: steps toward success. Gynecol Endocrinol 31 (2015), 501–505.
101. [101] Nordio, M., Proietti, E., The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci 16 (2012), 575–581.
102. [102] Minozzi, M., Nordio, M., Pajalich, R., The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci 17 (2013), 537–540.
103. *[103] Bevilacqua, A., Carlomagno, G., Gerli, S., et al. Results from the International Consensus Conference on myo-inositol and D-chiro-inositol in obstetrics and gynecology–assisted reproduction technology. Gynecol Endocrinol 31:6 (2015), 441–446.
104. *[104] Croze, M.L., Soulage, C.O., Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie 95:10 (2013), 1811–1827.